News

PRESS RELEASE - Salem, MA, USA - October 3rd, 2023 Genoskin Introduces ImmunoSafe: ISR Platform® with AUDACY - A Revolutionary Leap in Non-Clinical Local Toxicity Assessment Salem, MA, October 3rd, 2023 - Genoskin, a biotechnology company at the forefront of accelerating drug development, proudly announces the enhancement of its ISR Platform® with the integration of AUDACY, a state-of-the-art bioinformatics-based analyticalRead more

Top-level science through the eyes of an expert.The sixth Webinar. The sixth webinar in the Naked Immunology series is now scheduled on October 12, 2023 at 8 a.m. (PST), 11 a.m. (EST), 5 p.m. (CET). The webinar is open to English-speaking participants with a solid scientific background. Featured speaker is Dr. Laurent Reber, Laboratory Director at the Toulouse Institute forRead more

PRESS RELEASE - Toulouse, France - June 8th, 2023 Introducing MANTIS®: A Breakthrough Analytic Pipeline for Unraveling the Complexity of Inflammatory Skin Conditions. Toulouse, France, June 8, 2023 - Genoskin is proud to announce the publication of a groundbreaking scientific article in Science Advances, introducing a new analytic pipeline called MANTIS® (Multiplexed Annotated Tissue Imaging System). The article, authored byRead more

Top-level science through the eyes of an expert.The fifth Webinar. The fifth webinar in the Naked Immunology series is now scheduled on June 30, 2023 at 8 a.m. (PST), 11 a.m. (EST), 5 p.m. (CET). The webinar is open to English-speaking participants with a solid scientific background. Featured speaker is Dr. Cezmi Akdis, the director of the Swiss Institute ofRead more

Why testing & mitigating Injection Site Reactions is critical during drugs/vaccines development? Injection site reactions (ISR) are a common occurrence when a person receives an injection in the skin, such as a vaccine or self-administered biologics.These reactions occur due to the activation of the immune system at the injection site. When a foreign substance, such as a vaccine or medication,Read more

PRESS RELEASE - Washington D.C. - April 3, 2023 Genoskin and PharmaJet Announce Strategic Research Partnership to Advance Precision Vaccine Delivery Washington D.C., April 3, 2023 - Genoskin, a leading Franco-American TechBio company specializing in bio-stabilized immunocompetent human skin platforms, and PharmaJet, an innovative provider of Precision Delivery Systems (PDS), announce a strategic research partnership during the World Vaccine Congress.Read more